| Literature DB >> 33343539 |
Homa Bazireh1, Parvin Shariati1, Sadegh Azimzadeh Jamalkandi2, Ali Ahmadi3, Mohammad Ali Boroumand4.
Abstract
Probiotics are non-pathogenic microorganisms that can interact with the gastrointestinal microbiota. They have numerous beneficial health effects that include enhancement of the host immune response, antiallergic, antimicrobial, anti-cancer, and anti-inflammatory properties. Probiotics are capable of restoring the impaired microbiome of a dysbiotic gut. They can be isolated from different environments. However, it is frequently suggested that probiotics for human use should come from human sources. The objective of this study was to isolate and characterize novel probiotic strains from the saliva and feces of healthy human individuals. To meet the criteria for probiotic attributes, the isolates were subjected to numerous standard morphological and biochemical tests. These tests included Gram staining, catalase tests, antibiotic susceptibility testing, hemolytic and antagonistic evaluation, tolerance tests involving temperature, NaCl levels, pH and bile salts, adherence ability assays, and genotypic characterization involving 16S rRNA gene sequencing. From 26 saliva and 11 stool samples, 185 microbial strains were isolated. Based on morphological and biochemical characteristics, 14 potential probiotic candidates were selected and identified genotypically. The new strains belonged to Lactobacillus fermentum, Enterococcus faecium, and Enterococcus hire. The selected strains were non-hemolytic, showed high tolerance to low pH and bile salts, and strong adherence abilities. Furthermore, the strains displayed a wide range of antimicrobial activities, particularly against antibiotic-resistant pathogens such as methicillin resistant Staphylococcus aureus (MRSA). Moreover, five of the selected isolates demonstrated antiproliferative features against human colon cancer cell line (Caco-2). The results of this investigation confirm the diversity of microbial populations in the human gut and saliva, and since these strains are of human origin, they will highly likely display maximal activities in food and drugs set for human use. Hence, the new strains of this study require additional in vivo experiments to assess their health-promoting effects.Entities:
Keywords: Enterococcus; Lactobacillus; feces; lactic acid bacteria; microbiome; probiotics; saliva
Year: 2020 PMID: 33343539 PMCID: PMC7746552 DOI: 10.3389/fmicb.2020.597946
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Results of the morphological and biochemical tests carried out for selected isolates.
| Strains | SA 151 | SA 135 | SA 171 | SA 139 | SA 109 | SA 110 | SA 12 | SA 16 | ST 80 | ST 13 | ST 67 | ST 126 | ST 172 | ST 179 |
| Cell morphology | rod | rod | rod | rod | rod | rod | rod | rod | cocci | cocci | cocci | cocci | cocci | cocci |
| Gram | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Catalase | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
| Growth in presence of NaCl 3% | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Growth in presence of NaCl 4.5% | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Growth at 15°C | − | − | − | − | − | − | − | − | − | + | + | + | + | + |
| Growth at 45°C | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Carbohydrate fermentation | ||||||||||||||
| Glucose | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Galactose | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Maltose | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Mannose | − | − | − | − | − | − | − | − | − | + | + | + | + | + |
| Manitol | + | + | + | + | + | + | + | + | + | + | + | + | + | − |
| Cellobiose | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Rhamnose | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
| L−Arabinose | + | + | + | + | + | + | + | + | + | + | + | + | + | − |
| Fructose | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| L−xylose | + | + | + | + | + | + | + | + | + | − | − | − | − | − |
| Sorbitol | + | + | + | + | + | + | + | + | + | − | − | − | − | + |
| Sucrose | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Lactose | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Inositol | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
Acid tolerance and survival rate of selected isolates under acidic conditions.
| Strains | 0 h CFU/ml | 3 h CFU/ml | Survival rate (%) |
| SA 151 | 6.17 ± 0.1 | 6.01 ± 0.03 | 97.4% |
| SA 135 | 7.38 ± 0.01 | 7.33 ± 0.03 | 99.32% |
| ST 80 | 6.51 ± 0.01 | 6.46 ± 0.01 | 99.23% |
| SA 139 | 6.47 ± 0.1 | 6.17 ± 0.1 | 95.36% |
| SA 171 | 6.47 ± 0.1 | 5.60 ± 0.1 | 86.55% |
| SA 12 | 7.8 ± 0.06 | 7.3 ± 0.3 | 93.58% |
| SA 109 | 6.54 ± 0.06 | 5.17 ± 0.1 | 79.05% |
| SA 110 | 7.09 ± 0.08 | 5.87 ± 0.02 | 82.79% |
| SA 16 | 6.47 ± 0.03 | 5.54 ± 0.06 | 85.62% |
| ST 13 | 7.17 ± 0.1 | 6.17 ± 0.1 | 86.05% |
| ST 67 | 6.49 ± 0.01 | 6.30 ± 0.2 | 97.07% |
| ST 126 | 6.47 ± 0.1 | 5.30 ± 0.2 | 81.91% |
| ST 172 | 7.14 ± 0.03 | 5.65 ± 0.04 | 79.13% |
| ST 179 | 6.90 ± 0.05 | 5.47±+0.1 | 79.27% |
FIGURE 1Percentage growth inhibition (suppression) of the 14 selected isolates by bile salts.
Antimicrobial activities against ten pathogens.
| Strains | MRSA | |||||||||
| SA 151 | 15 | 13 | 15 | 10.5 | − | 15.5 | 15.5 | 11 | 20 | − |
| SA 135 | 15 | 15 | 16 | 15 | − | 17 | 20 | − | 11 | − |
| ST 80 | 12 | 16 | 18 | 11 | − | 15 | 22 | − | 17 | − |
| SA 139 | – | 10 | 13 | 15 | 10 | 13 | 16 | 10 | − | − |
| SA 171 | 18 | − | 15 | 15 | − | 20 | 19 | − | − | − |
| SA 12 | − | − | 14 | 12 | − | 10 | 12 | 12 | − | − |
| SA 109 | − | − | 10 | 12 | − | 15 | 21 | − | 30 | − |
| SA 110 | − | − | 10 | 10 | − | 12 | 20 | − | 25 | − |
| SA 16 | − | − | 12 | 12 | − | 14 | 15 | − | 21 | − |
| ST 13 | − | 14 | 10 | − | 14 | 12 | − | 10 | − | − |
| ST 67 | − | 13 | 9 | − | − | − | − | 10 | − | − |
| ST 126 | − | 13 | 13 | − | 15 | 17 | − | 15 | − | − |
| ST 172 | − | − | − | − | − | 10 | − | 10 | − | − |
| ST 179 | − | 10 | − | − | − | − | − | − | − | − |
Antibiotic susceptibility test results.
| Strains | Gentamycin | Cefixime | Penicillin | Chloramphenicol | Streptomycin | Erythromycin | Ampicillin | Trimethoprim | Kanamycin | Vancomycin | Rifampin | Azithromycin | Clindamycin |
| SA 151 | S | S | S | S | R | S | S | S | R | R | S | S | S |
| SA 135 | R | R | S | S | R | S | S | R | R | R | S | S | S |
| ST 80 | R | R | S | S | R | S | S | R | R | R | S | S | I |
| SA 171 | S | S | R | S | R | S | S | S | R | R | S | S | S |
| SA 139 | R | R | S | S | R | I | S | R | R | S | R | I | S |
| SA 109 | S | R | S | S | S | S | S | R | R | R | S | S | S |
| SA 110 | S | S | S | S | R | S | S | S | R | R | S | S | S |
| SA 12 | R | I | S | S | R | I | S | R | R | S | R | I | S |
| SA 16 | S | S | S | S | R | S | S | S | R | R | S | S | S |
| ST 13 | S | R | R | S | R | S | S | R | R | S | R | S | S |
| ST 67 | S | I | R | S | R | S | S | R | R | S | R | S | S |
| ST 126 | S | S | R | S | R | I | S | R | R | S | R | S | S |
| ST 172 | S | I | S | S | R | S | S | R | R | S | R | R | S |
| ST 179 | R | R | S | S | R | S | S | S | R | R | S | I | I |
The adhesion ability of the selected isolates.
| Strains | Adhesion | Strains | Adhesion |
| SA 135 | Strong | ST 67 | Strong |
| SA 171 | Strong | ST 80 | Moderate |
| SA 139 | Strong | SA 151 | Moderate |
| SA 12 | Strong | SA 109 | Moderate |
| ST 126 | Strong | SA 110 | Moderate |
| ST 172 | Strong | SA 16 | Moderate |
| ST 179 | Strong | ST 13 | Moderate |
Candidate probiotics identified based on percentage similarity of the 16s rRNA sequence to those available in the GenBank database.
| Accession Number | Name | Similarity (%) | Strains |
| ST 80 | 84.44% | MT815471 | |
| SA 151 | 90.43% | MN128866 | |
| SA 135 | 98.30% | MN475882 | |
| SA 12 | 98.65% | MN475960 | |
| SA 139 | 98.93% | MN128688 | |
| ST 13 | 98.97% | MN475959 | |
| SA 109 | 99.00% | MN475903 | |
| ST 172 | 99.04% | MN128647 | |
| SA 171 | 99.15% | MN475879 | |
| SA 110 | 99.20% | MN475967 | |
| ST 179 | 99.35% | MN147877 | |
| SA 16 | 99.43% | MN475920 | |
| ST 126 | 99.71% | MN148088 | |
| ST 67 | 99.78% | MN475904 |
FIGURE 2Phylogenetic tree of the 14 probiotic isolates based on 16s rRNA sequences. The tree was constructed by the MEGAX software using the bootstrap method.
Percentage of cell surface hydrophobicity of candidate probiotic strains.
| Strains | Auto-aggregation (%) | Hydrophobicity (%) | Strains | Auto-aggregation (%) | Hydrophobicity (%) |
| SA 151 | 16.23 ± 0.002 | 55.84 ± 0.08 | SA 16 | 15.77 ± 0.004 | 27.12 ± 0.007 |
| ST 80 | 12.89 ± 0.002 | 20.69 ± 0.003 | SA 110 | 6.29 ± 0.002 | 11.51 ± 0.04 |
| SA 135 | 13.13 ± 0.004 | 69.68 ± 0.01 | ST 13 | 17.39 ± 0.002 | 1.45 ± 0.01 |
| SA 12 | 7.62 ± 0.006 | 41.14 ± 0.003 | ST 172 | 11.30 ± 0.002 | 0 |
| SA 171 | 2.23 ± 0.002 | 11.48 ± 0.007 | ST 179 | 33.43 ± 0.007 | 6.44 ± 0.01 |
| SA 139 | 11.81 ± 0.002 | 0 | ST 67 | 13.82 ± 0.007 | 5.26 ± 0.01 |
| SA 109 | 14.79 ± 0.005 | 32.24 ± 0.002 | ST 126 | 10.57 ± 0.007 | 3 ± 0.01 |
FIGURE 3The cytotoxic effects of bacterial culture free supernatants on the CaCo-2 cell line at different supernatant concentrations and incubation periods. The five probiotic candidates that were assessed included SA 151, SA 171, SA139 and SA 135.